Guide for Authors

  • All journal information and instructions compiled in one document (PDF) in just one mouse-click Author information pack

    INTRODUCTION
    • Disclaimer
    • Contact details for submission
    BEFORE YOU BEGIN
    • Ethics in publishing
    • Human and animal rights
    • Conflict of interest
    • Submission declaration
    • Authorship
    • Randomized trials
    • Copyright transfer and ownership of data
    • Special subject repositories
    • Funding body agreements and policies
    • Open access (OA)
    • Language (usage and editing services)
    • Informed consent and patient details
    • Submission
    • Style
    • Brevity
    • Undocumented claims (eg, "firstedness," "safe and effective")
    • Trade names
    • Sections/article type guidelines
    • Article structure
    • Title page
    • Abstract
    • Graphical abstract
    • Capsule summary
    • Key words
    • Classifications
    • Abbreviations and acronyms
    • Acknowledgements
    • Artwork
    • Illustration services
    • Figure legends
    • Tables
    • Permissions and patient consent forms
    • Video data
    • AudioSlides
    • Supplementary data
    • Supplements
    • Procedure for review
    • Expedited review and publication
    AFTER ACCEPTANCE
    • Use of the Digital Object Identifier
    • Proofs
    • Reprints
    • Electronic publishing
    AUTHOR INQUIRIES



    The Journal of the American Academy of Dermatology is a refereed journal designed to meet the continuing education needs of the Academy members and the international dermatologic community. The Journal bases its policies on the guidelines set forth by the International Committee of Medical Journal Editors (http://www.icmje.org).

    Disclaimer

    Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), Publisher, or Academy. The Editor(s), Publisher, and Academy disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any products or services advertised in this publication, nor do they guarantee any claim made by the manufacturer of such products or services.

    Contact details for submission

    EDITOR
    Bruce H. Thiers, MD
    Medical University of South Carolina
    Charleston, South Carolina

    DEPUTY EDITOR
    Dirk M. Elston, MD
    Ackerman Academy of Dermatopathology
    New York, New York

    EDITORIAL OFFICE
    Detra Davis
    Managing Editor
    Journal of the American Academy of Dermatology
    930 E. Woodfield Rd.
    Schaumburg, IL 60173
    Phone: 847-240-1005
    Fax: 847-240-0101
    E-mail: JAADManagingEditor@aad.org

    Anna Krueger
    Editorial Assistant
    Journal of the American Academy of Dermatology
    930 E. Woodfield Rd.
    Schaumburg, IL 60173
    Phone: 847-240-1706
    Fax: 847-330-8907
    E-mail: JAADEdAsst@aad.org
    Contact for questions about manuscript preparation, submission, and review.

    PUBLISHER
    Elsevier Inc.
    3251 Riverport Lane
    Maryland Heights, MO 63043

    Susan M. Kell, Senior Journal Manager
    Phone: 215-239-3380
    Fax: 215-239-3388
    E-mail: s.kell@elsevier.com
    Contact for questions about the proof of your accepted paper.

    Ethics in publishing

    For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

    Human and animal rights

    If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

    Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees, from which a patient could be identified is permitted unless express written permission from the patient/family is provided at the time of manuscript submission. Studies involving live human or animal subjects must have been approved by the authors' Institutional Review Board or its equivalent. A copy of the IRB approval letter must be included with the submission or sent to the Journal office under separate cover. If the IRB has exempted the research from review, a copy of the letter of exemption must accompany the submission. Please state your IRB status on the title page. If applicable, IRB approval must be mentioned in the Methods section of all manuscripts. All clinical investigations must have been conducted according to the Declaration of Helsinki principles. If the Methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers. 

    Submissions of survey research must include: 1. A copy of the letter documenting Human Subject Institutional Review Board (IRB) approval. 2. A copy of the survey instrument. (The editors, in consultation with the authors, will determine if the survey instrument should be published and whether it should be published as an online-only Appendix.) The manuscript's Methods section must: 1. Attest that the use of any proprietary sampling contact information (eg, mailing list) was approved by its owner. 2. Provide IRB protocol approval number and date. 3. Describe how the survey instrument was developed and piloted, and whether/ how the survey was validated. During the review process, editors and reviewers may request a copy of the approved study protocol to aid in their evaluation of the study.

    Conflict of interest

    All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

    The Journal requires all authors to acknowledge, in the comments section of EES (http://ees.elsevier.com/jaad.), all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. The title page must also include a publishable statement disclosing any associations, current and over the past 5 years, that might pose a conflict of interest. These include but are not limited to employment, royalties, consultant arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated in the publishable disclosure statement. If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, authors should list them in the comments section of EES (http://ees.elsevier.com/jaad). They should also explain these interests as well as the reason for the need for confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests or conflicts of interest that might interfere with one's objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests, if any, with the officers of the American Academy of Dermatology. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.

    Each author must sign an authorship statement and conflict of interest statement. Both of these must be submitted with each manuscript. Both forms are available for download from the JAAD Web site (http://www.jaad.org/content/auth_page).

    Please save all PDF files (authorship forms, conflict of interest forms, copyright transfer forms, IRB documentation, permissions, etc.) as reduced size PDFs in order to reduce file download times. To do this, please open your PDF files, select "Save As," and then select the "Reduced Size PDF" option.

    Submission declaration

    Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

    Authorship

    All authors must have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

    The Journal's authorship criteria are adapted from those of the International Committee of Medical Journal Editors and are delineated on the Authorship Statement, which must be signed by each author.

    Role of writers, "ghost writers," and other "third parties" involved in manuscript development and production
    The involvement, nature of involvement, and affiliation or support of any medical writers, "ghost writers," or other individuals or companies or third parties participating in the development or writing of any papers must be noted and explained in the cover letter and in a publishable statement on the manuscript title page. (This does not include tasks such as typing or photocopying.) This statement will be published as part of the first-page footnotes. All individuals involved in the preparation and writing of each paper who meet the JAAD's authorship criteria (see our Authorship Statement) must be listed as authors. The names, highest academic degree, and affiliations of any persons who contributed to writing the paper or analyzing the data who do not meet authorship criteria must be included in the paper's Acknowledgements along with a disclosure of any pertinent conflicts of interest. Individuals listed in the Acknowledgements because of such contributions to the work should provide written consent. The use of "ghost writers" or any author employed by an entity with a commercial interest in any product discussed is rarely appropriate for any manuscript and is strictly prohibited for any CME-accredited activity.

    Randomized trials

    Randomized trials must be submitted in a format consistent with the CONSORT statement, along with a completed CONSORT manuscript submission checklist. The word "random" or "randomized" should be in the title. The updated CONSORT guidelines can be accessed by visiting http://www.consort-statement.org . A copy of the "CONSORT Checklist for Authors Submitting Reports of Randomized Controlled Trials" may be downloaded from the JAAD Web site ( http://www.jaad.org/content/auth_page).

    Any reports of clinical trials must be registered by the time of submission. The registry must meet ICMJE criteria (available at http://www.icmje.org). The registry at http://www.clinicaltrials.gov meets such requirements. When submitting a manuscript that reports a clinical trial, authors are asked to provide the date the first patient enrolled, the date the study was registered, and the registration number.

    Copyright transfer and ownership of data

    In accordance with the Copyright Act of 1976, which became effective January 1, 1978, the following statement signed by each author must accompany the manuscript submitted: "I, the undersigned author, transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I have reviewed and approve the submitted version of the manuscript and agree to its publication in the Journal of the American Academy of Dermatology." A copyright transfer form may be downloaded from the JAAD Web site (http://www.jaad.org/content/auth_page). Author(s) will be consulted, whenever possible, regarding republication of material. All authors must have access to the data presented and the authors and sponsor (if applicable) must agree to share original data with the editor if requested.

    Please save all PDF files (authorship forms, conflict of interest forms, copyright transfer forms, IRB documentation, permissions, etc.) as reduced size PDFs in order to reduce file download times. To do this, please open your PDF files, select "Save As," and then select the "Reduced Size PDF" option.

    Special subject repositories

    Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles, such as those funded by the National Institutes of Health, under its Public Access policy (see elsevier.com for more detail on the policy). Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months after final publication. The version of the article provided by Elsevier will include peer-review comments incorporated by the author into the article.

    Funding body agreements and policies

    Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

    Open access (OA)

    This journal offers authors a choice in publishing their research:

    Open Access
    • Articles are freely available to both subscribers and the wider public with permitted reuse
    • An Open Access publication fee is payable by authors or their research funder
    Subscription
    • Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)

    All articles published Open Access will be immediately and permanently free for everyone to read and download. The JAAD requires “CC BY-NC_ND” license except where otherwise mandated by a government funding body:
    Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

    To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.
    Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

    The Open Access publication fee for this journal is $3,000, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing. There is no publication fee for articles accessible only by subscribers.

    Language (usage and editing services)

    Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

    Informed consent and patient details

    Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals, http://www.elsevier.com/patient-consent-policy. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

    Submission

    Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

    Submit your article
    Please submit your article via http://ees.elsevier.com/jaad.

     The site provides instructions for manuscript submission as well as a tutorial for authors. Word, WordPerfect, RTF, and Text files will be accepted; Word and WordPerfect are preferred. Please note that online-only materials should be provided in the same format. Questions about the program may be addressed to JAADEdAsst@aad.org. All manuscript submissions must include the copyright transfer form, the conflict of interest disclosure form, the authorship statement (attestation) form, and the manuscript submission checklist. These forms can be downloaded from either our Web site (http://www.jaad.org/content/auth_page) or EES (http://ees.elsevier.com/jaad). Please scan the completed forms and upload them to EES with your submission. If this presents a problem, please contact support@elsevier.com.

    Original manuscripts will be considered for publication. Correct preparation of the manuscript will expedite the review and publication procedures. Please note the following requirements.

    The original page-numbered copy of the manuscript must be double-spaced. The title page should be numbered page 1. Please line number all submissions before creating the PDF. This continuous line numbering will help our reviewers with writing their comments and should speed the peer-review process. To add line numbers to your Word manuscript file, select File/Page Setup/Layout/Line Numbering/Add line numbering/Continuous, and save the changes.

    Style

    Manuscripts must conform to acceptable English usage. Consult the latest edition of The Chicago Manual of Style by The University of Chicago Press or the Manual of Style by the American Medical Association for current usage. Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.

    Brevity

    Brevity is appreciated. Authors should avoid repeating the same information in the Abstract, Introduction, and Discussion.

    Undocumented claims (eg, "firstedness," "safe and effective")

    Please do not claim that your report is the first reported case. If such a claim is deemed necessary, authors should explain their reasoning in the cover letter and provide a detailed Appendix describing how they came to this conclusion. Describe search strategies, search terms, databases queried, and how far back these were checked. Also list textbooks and monographs that were searched to substantiate the claim. Similarly, the phrase "safe and effective" should be reserved for FDA-approved product labeling based on registered phase III trials. In other settings, the term should be avoided entirely. Acceptable terminology for a case series would include the sentence "Our patients demonstrated positive responses and the treatment was well tolerated."

    Trade names

    Trade names and brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should be placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in the text. Thereafter, only generic names should be used throughout the article.

    Sections/article type guidelines

    Authors, please note: JAAD is contractually limited in the number of pages that can be published each month. Manuscripts should be concise and to the point. Inclusion of textbook-type material is strongly discouraged, as is repetition of the same statements in the Introduction and Discussion. The Introduction and Discussion should pertain directly to the study being reported, and not contain a lengthy review of a disease entity or its treatment.

    Continuing Medical Education (CME)
    In-depth, substantiated, educational articles presenting core information for the continuing professional development of the practicing dermatologist. CME articles should not be simply reviews but should present new information not readily available in textbooks.

    To have manuscripts considered for publication in the JAAD as certified CME activities, authors must first complete and submit proposal worksheets and manuscript outlines for approval by the CME Planning Workgroup and Deputy Editor (available at http://www.jaad.org/content/auth_page). Submit this proposal along with a proposed outline of the manuscript to jaadmanagingeditor@aad.org.

    Unless a specific exemption is granted by the Deputy Editor, all CME submissions should be written in 2 articles (Part I and Part II). A proposal and outline must be submitted for each part, as these will also be submitted as individual manuscripts. Should the proposals be accepted, the author will be granted permission to move forward and submit the manuscripts. An accepted proposal does not guarantee that the written manuscript will be accepted for publication. An approved proposal only provides authority to have a manuscript considered for the CME section. Authors will be required to include their Education Director-approved proposal forms with their CME submissions, which will be provided to them at the time the proposal is accepted.

    Each manuscript should: 1) contain bulleted key points preceding each major section; 2) include summary tables when possible, as well as separate algorithms for evaluation and management when appropriate. Please note that the key points are intended as a substitute for the capsule summary, which is not a part of the CME article format. Any unique pediatric or geriatric manifestations should be included in the text. Recommended tests should have an impact on therapy and should be supported by outcomes data. The word count for each part of the CME article should not exceed 3500 words excluding the abstract, references, figures, and tables. Authors who submit an article they wish to be considered for CME certification may not recommend peer reviewers. Only manuscripts submitted with an approved proposal and outline will be considered.

    The level of evidence should be cited whenever recommendations are made. Level IA evidence includes evidence from meta-analysis of randomized controlled trials; level IB evidence includes evidence from at least one randomized controlled trial; level IIA evidence includes evidence from at least one controlled study without randomization; level IIB evidence includes evidence from at least one other type of experimental study; level III evidence includes evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; and level IV evidence includes evidence from expert committee reports or opinions or clinical experience of respected authorities, or both. All therapeutic recommendations should be accompanied by a table indicating their level of evidence, with a definition of the different levels included as a footnote.

    To qualify for CME credit, authors must provide for each CME article 2 clinical vignettes, each followed by 2 or 3 questions that evaluate clinical competence acquired as a result of the CME activity. The questions should reflect appropriate clinical practice rather than simply testing factual knowledge. Suitable questions assess the learner's ability to diagnose or treat a condition appropriately after reading the CME article. Guidelines for question writing can be found at http://www.jaad.org/webfiles/images/journals/ymjd/dos_donts.pdf.

    The AAD offers short educational modules on CME planning free of charge. To learn more about CME planning, visit http://www.abcsofcme.org.

    Original Articles
    Original, in-depth clinical and investigative laboratory research papers. A structured abstract and capsule summary should be included. A description of the type of study that was done (case series, case-control, cohort, cross-sectional, randomized controlled trial, ecologic, etc) should be included in the Methods section. Authors of randomized control trials must follow the guidelines presented in the CONSORT statement (http://www.consort-statement.org/), and submit a completed CONSORT manuscript checklist with their manuscript. Similar guidelines for authors of epidemiologic studies are included in the STROBE statement (http://www.strobe-statement.org/Checklist.html), and for studies of diagnostic accuracy in the STARD statement (http://www.stard-statement.org/). Citation of levels of evidence is encouraged for any article when appropriate. Information on rating levels of evidence can be found in the instructions to authors of CME articles. The word count should not exceed 2500 words excluding the abstract, references, figures, and tables.

    Reviews
    A current review of a disease or treatment. The word count should not exceed 2500 words excluding the abstract, references, figures, and tables.

    Dermatologic Surgery
    Articles emphasizing the surgical aspect of dermatology. If applicable, a description of the type of study that was done (case series, case-control, cohort, cross-sectional, randomized controlled trial, ecologic, etc) should be included in the Methods section. A structured abstract and capsule summary should be included. The word count should not exceed 2500 words excluding the abstract, references, figures, and tables.

    Dermatopathology
    Articles emphasizing the histopathological changes in skin disease. If applicable, a description of the type of study that was done (case series, case-control, cohort, cross-sectional, randomized controlled trial, ecologic, etc) should be included in the Methods section. A structured abstract and capsule summary should be included. The word count should not exceed 2500 words excluding the abstract, references, figures, and tables.

    Dermatoethics Consultations
    These articles examine ethical controversies faced by the practicing dermatologist. Two types of submissions are welcomed: 1) Short case-based articles (up to 1750 words and 5 references). Each submission should begin with a case scenario illustrating the ethical or professionalism issue to be discussed, accompanied by a multiple choice question offering four possible actions to deal with the problem. This is followed by a balanced discussion of the subject, with special focus on the ethical issues, and an analysis of the case based on the multiple choice options presented with the author's recommended resolution. 2) "Dermatoethics consultation requests", in which readers can submit short cases or scenarios for commentary and analysis. These will be selected for print or online commentary written by the editors or invited experts.

    Editorials/Commentaries
    Brief, provocative, opinionated communications, not necessarily documented, on a limited subject. The word count should not exceed 750 words excluding the abstract, references, figures, and tables.

    Letters: Notes & Comments and Research Letters
    The Letters department has two sections. Letters commenting on material previously published in the Journal will be considered for the Notes & Comments section. These will be sent for response to the authors of the article being commented upon. This response may be published or sent directly to the commentator at the discretion of the editor. Questions or comments that could be addressed directly by the authors (including complaints about missed citations) should be sent directly to them, rather than involving the Journal as an intermediary.

    New or preliminary research findings and early reports of therapeutic trials in one or several patients may be considered for publication as Research Letters. Research Letters should not be subdivided into sections, eg, Introduction, Methods, Results, Discussion, etc. The type of study that was done (case series, case-control, cohort, cross-sectional, randomized controlled trial, ecologic, etc) should be noted. Conclusions based on uncontrolled trials and/or limited experience should be stated in appropriately tentative terms.

    Letters must not exceed 500 words and should not cite more than five references. Up to two figures or tables may be included. Each part of a multi-part figure is counted toward the maximum allotment, eg, a figure 1A and 1B are considered 2 figures.

    JAAD no longer publishes Case Letters. All individual case studies or small case series should now be submitted to our new open access journal, JAAD Case Reports, at http://ees.elsevier.com/jdcr.

    Book Reviews
    Books and monographs (domestic and foreign) will be reviewed depending on their interest and value to subscribers. Send books to the Editorial Assistant, Anna Krueger, Journal of the American Academy of Dermatology, 903 E. Woodfield Rd., Schaumburg, IL 60173. No books will be returned. Journal guidelines for writing book reviews are available online ( http://www.jaad.org/article/S0190-9622(08)00647-6/fulltext). Book reviews are limited to 375 words and are designated for online-only publication.

    In Memoriam
    A tribute to a departed colleague who has contributed significantly to the field of dermatology. In Memoriam submissions are limited to 500 words and are designated for online-only publication.

    Images in Dermatology
    This is an online-only feature that consists of 1-3 clinical or histologic images along with a short (100 word or less) description of any relevant history. Short (up to 1 minute) video clips are also acceptable. Included are 3 questions, each with 5 answer choices. Each of the 5 choices must be accompanied by a 1 or 2 sentence discussion explaining why it is correct or incorrect. The discussion of all 5 choices is limited to a total of 250 words for each question. Authors may cite up to 5 references. The submitted title, consisting of less than 8 words, should be descriptive and not indicate the diagnosis or correct answer choice. All submissions must be through EES. If identifying information or figures are included, express written permission from the patient must be provided at the time of manuscript submission. Material may not have been submitted or published elsewhere.

    Dermoscopy Case of the Month
    This online-only feature allows clinicians to hone their dermoscopy skills. Submissions should be structured as follows:

    • Clinical presentation
    • Confocal microscopy appearance(optional)
    • Dermoscopic appearance
    • Histologic diagnosis
    • Key message

    Manuscripts should be no longer than 250 words and may include up to 4 figures (a clinical image, a dermoscopic image, a confocal microscopy image [optional], and a histologic image when relevant); references (no more than 2) are optional.

    Pearls
    This online-only feature allows clinicians to communicate the "tricks of the trade" that help them practice more effectively and efficiently. Three types of pearls will be published: (1) Clinical Pearls, (2) Therapeutic Pearls, and (3) Surgical Pearls. Submissions should be structured as follows:

    • Clinical (or Therapeutic, or Surgical) challenge
    • Solution

    Manuscripts should be no longer than 250 words. Figures (no more than 2) and references (no more than 2) are optional. Please indicate whether your Pearl is Clinical, Therapeutic, or Surgical within the cover letter for the submission.

    Article structure

    Title page

    On the title page, include the title, authors' full names, highest earned academic degrees, and institutional affiliations and locations. Include a separate word count for the abstract, capsule summary, and text (excluding references, figures, and tables). Please include a figure, table, online-only figure, and online-only table count. Please state your IRB status on the title page. The title page must also include a statement of all funding sources for the work as well as a publishable conflict of interest statement (see above for details). Designate one author as correspondent (provide address, telephone and fax numbers, and e-mail address) to receive communications from the Editorial Office and galley proofs from the publisher. The name and address of the author who will receive reprint requests should be noted if different from the correspondent. The corresponding author should promptly inform the managing editor (JAADEdAsst@aad.org) of any change in e-mail or mailing address.

    Abstract

    Unless otherwise stated, all articles must be accompanied by a typed, double-spaced abstract not exceeding 200 words. Abstracts of papers submitted for publication in the Original Articles, Dermatopathology, and Dermatologic Surgery sections should be structured as follows:

    • Background: What is the major problem that prompted the study?
    • Objective: What is the purpose of the study?
    • Methods: What type of study was done (case series, case-control, cohort, cross-sectional, randomized controlled trial, ecologic, etc)? How was the study done?
    • Results: What are the most important findings?
    • Limitations: What are the limitations of the study?
    • Conclusion: What is the single most important conclusion?
    Abstracts for Reviews may be structured or unstructured at the discretion of the author. Note that abstracts should not be submitted with other article types.

    Graphical abstract

    A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.
    Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: Illustration Service.

    Capsule summary

    Papers submitted for publication in the Original Articles, Review, Dermatologic Surgery, and Dermatopathology sections must include a capsule summary of up to 50 words. The capsule summary should not contain abbreviations, and should be composed of 3 bulleted statements which address the following:

    • (First bullet) What is already known on this topic
    • (Second bullet) What this article adds to our knowledge
    • (Third bullet) How this information impacts clinical practice and/or changes patient care

    Because the CME article includes a list of bulleted key points for each section, a capsule summary is not required.

    Key words

    A list of 6-10 key words (eg, Key words: sunscreen; UVA protection; UVB protection) should appear after the Abstract.

    Classifications

    Select at least 6 classifications to facilitate matching the manuscript with reviewers. You can do this in EES by clicking 'Select Document Classifications' to open a window containing a list of the classifications pertaining to the Journal. Then click the check-box next to any classification you wish to select. Click 'Submit' when you are done. 

    Abbreviations and acronyms

    Only standard abbreviations are to be used. Consult Scientific Style and Format by the Council of Biology Editors or the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable and they should be avoided in the abstract whenever possible. A laboratory or chemical term or a disease process must be spelled out at first mention, with the acronym or abbreviation following in parentheses. List all abbreviations and acronyms on a separate page within the manuscript document before the references.

    Acknowledgements

    Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

    Artwork

    For specific information about how to format your artwork, please visit http://www.elsevier.com/artworkinstructions.

    Image manipulation
    Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

    Black and white graphs must be legible and clearly printed. The fill for bar graphs or pie charts should be distinctive; avoid shading or dotted patterns. Use thick, solid lines and bold, solid type. Place lettering on a white background; avoid reverse type (white lettering on a dark background). All lettering must be done professionally and should be in proportion to the drawing, graph, or photograph. Typewritten or freehand lettering is unacceptable. Consistency in size within the article is strongly preferred. Any special instructions regarding sizing should be clearly noted.

    For color photographs, if prints have been enhanced, a preference for reproduction should be noted. The quality of the reproduction depends entirely on the quality of the illustrations submitted. Please note that 35 mm transparencies are normally enlarged to twice their original size. If it is important to deviate from this standard, please indicate when file material is submitted. Top for each print (and transparency) must be noted.

    Figures and tables
    Tables, figures, and legends should supplement, not duplicate, the text. Clinical photographs should be of high quality without distracting backgrounds. Please visit our website (http://www.jaad.org) for examples of acceptable and unacceptable illustrations. A reasonable number of halftone photographs and line drawings will be published at no extra charge to the author. Color illustrations will be reviewed by the Editor and those considered appropriate will be published free of charge to the authors. Figures must be cited in the text and numbered in order of mention. Figures must have an arrow marking the top edge and they must be numbered consecutively (ie, 1, 2, 3). Multi-part figures must be marked clearly (ie, 1A, 1B, 1C). Legends should start with the name of the disease or condition being depicted. For graphics files, use Adobe Photoshop and save the files in either TIF or EPS format. DO NOT SUBMIT figures in Word, PowerPoint, or Excel formats. If they have not already done so, authors will be contacted to provide print-quality figures after their articles have been accepted.

    Figure format
    Figures may be submitted in electronic format. All images should be at least 5 inches wide. Images should be provided in TIF, EPS, or JPEG format. Graphics software such as Photoshop and Illustrator, not presentation software such as Microsoft Word, PowerPoint, CorelDraw, or Harvard Graphics, should be used in the creation of the art. Color images must be CMYK and at least 300 DPI. Gray scale images should be at least 300 DPI. Combinations of gray scale and line art should be at least 1200 DPI. Line art (black and white or color) should be at least 1200 DPI. Please note that online-only figures should follow these specifications as well.

    Illustration services

    Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

    Figure legends

    Figure legends should start with the name of the condition or disease being depicted. Legends should be typed double-spaced and inserted after the references within the manuscript document. If an illustration has been published previously, full credit to the original source must be given in the legend and permission to reprint must have been obtained from the copyright holder. For histologic/microscopic figures, the legend must specify stain. Arrows and arrowheads should be used freely to clarify findings. Please note that online-only figures also require legends.

    Tables

    Tables should be self-explanatory and numbered sequentially in Roman numerals in order of their mention in the text. Tables should be submitted in Word, WordPerfect, RTF, or Text formats; Word and WordPerfect are preferred. A brief title should be provided for each. If a table, or any data therein, has been published previously, full credit to the original source must be given in a footnote. Please note that online-only tables should follow these specifications as well.

    Permissions and patient consent forms

    Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied upon submission by written permission for their use from the copyright owner and the original author along with complete information as to their source.

    Patient consent forms for publication of recognizable photographs must be sent to the Editorial Office upon submission of the article. Patients must be identified by numbers and/or letters, not by name, initials, or hospital record number. Institutional consent must also be available.

    Patient consent must accompany recognizable photographs of patients at the time of submission. Photographs and text (such as details in the case report or genetic pedigree) must be deidentified to protect patient confidentiality unless patient consent has been documented. In the event that patient consent has not been documented, please crop the photo and/or obstruct the eye region in such a manner that the patient cannot be recognized. The altered figure must be unidentifiable unless documentation of patient consent is provided.

    Personal communications should not be cited in the reference list but may appear parenthetically in the text. References must be identified in the text by superscript Arabic numerals in order of their mention. References should not be formatted as footnotes, but should appear in a list at the end of the text. The reference list should be typed double-spaced and in numeric sequence. The format should conform to that set forth by the International Committee of Medical Journal Editors and the National Library of Medicine (http://www.nlm.nih.gov/bsd/uniform_requirements.html). Journal titles should conform to the abbreviations in Cumulated Index Medicus.

    Reference links
    Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

    Reference style
    List the first six authors followed by et al.:

    • For journal articles: Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1997;36:331-5.
    • For books: Hunt TK, editor. Wound healing and wound infection: theory and surgical practice. New York: Appleton-Century- Crofts; 1980.
    • For chapters in books: McNutt NS, Fishman PM. Metastatic tumors. In: Farmer ER, Hood AP, editors. Pathology of the skin. Norwalk (CT): Appleton & Lange; 1990. p. 465-78.
    • For electronic media: Bhatia A, Prakash S. Topical phenytoin for wound healing. Dermatology Online Journal. Available at: http://dermatology.cdlib.org. Accessed November 3, 2004.
    • For articles published online ahead of print: Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol doi:10.1016/ j.jaad.2004.08.007. Published online October 29, 2004.

    Journal abbreviations source
    Journal names should be abbreviated according to the List of Title Word Abbreviations: http://www.issn.org/services/online-services/access-to-the-ltwa/.

    Video data

    Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

    AudioSlides

    The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

    Supplementary data

    Supplementary data may be included with the submission and is meant to support the scientific thesis embodied in the manuscript. It may be uploaded at the time of submission or later at the request of reviewers. It is generally not meant for publication but may be published online at the discretion of the editor. Please upload any supplementary text in document format (eg, .doc). Please upload each supplementary figure as a separate file in .tif or .jpg format. Please upload each supplementary table as a separate file in document format (eg, .doc). Please include a supplementary figure legend. On the title page, please include a supplementary figure and supplementary table count.

    Supplements

    The Journal follows the guidelines for supplements established by the International Committee of Medical Journal Editors. These guidelines are included in the document entitled "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," which can be found at http://www.icmje.org. Supplements undergo peer review and are processed in the same fashion as regular submissions to the Journal. All manuscript submission requirements, including clear disclosure of authorship contributions, must be satisfied for each paper. Inquiries about proposed supplements should be directed to the Editor before submitting the supplement. Please note Journal policy on the use of the word "unrestricted" in the description of educational grants: The use of the term "unrestricted" will be limited to situations in which the granting institution has no influence on the selection of the subject, speakers, or authors. In circumstances in which the granting institution has had such influence (as, for example, in organizing a symposium or supplement on a particular subject), it is nonetheless required that the granting organization have no influence over the content of the articles. It is also understood that the authors assume full responsibility for the content of the articles and for complete disclosure of all funding sources, potential conflicts of interest, role of any sponsor, and role of any third parties involved in the preparation or writing of the manuscripts.

    Procedure for review

    The Journal employs a confidential and anonymous peer review process to evaluate submitted papers for possible publication. A small number of papers are rejected after in-house editorial review when editors deem that the paper is not appropriate for the Journal or is not of sufficient quality to warrant further evaluation. The overall acceptance rate is less than 50%.

    The author may suggest several reviewers for the manuscript. We will attempt to use at least one suggested reviewer. The editorial staff will review the manuscript and will ordinarily send it to at least two reviewers. Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, and quality of illustrations. First decisions (accept, revise, reject) are usually made within four to six weeks; longer delays are possible. Some degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be accepted, only that it will be reconsidered, perhaps after additional peer review. Because space in the Journal is limited, the final editorial decision rests not only on the validity of the report and the opinions of the reviewers, but also on the editors' judgment of a paper's novelty, clarity, importance, and likely degree of interest to the readership.

    Expedited review and publication

    Authors who feel that their paper should receive expedited review and/or rapid publication should request it and explain their rationale in the Comments section of EES (http://ees.elsevier.com/jaad/). They should also send a separate explanatory e-mail to the managing editor: JAADEdAsst@aad.org. The time frame for rapid review is ordinarily 2 to 4 weeks; for expedited online publication, 3 to 6 weeks from the date of acceptance of the final revision. Authors are reminded that as a monthly clinical journal, we do not operate on the time frame of a weekly and do not ordinarily publish "news" items.

    Use of the Digital Object Identifier

    The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
    http://dx.doi.org/10.1016/j.physletb.2010.09.059
    When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

    Proofs

    One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html.
    If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

    Reprints

    Reprint order forms will be sent to authors after the manuscript has been accepted. The provision of reprints by the author is optional.

    Electronic publishing

    Articles in Press: Prior to print publication, most articles are now published "online ahead of print" in our Articles in Press section in the JAAD Online at http://www.jaad.org. Some articles are published online only in our JAAD Online section ("online-only publication"). More specifically, all Case Letters are designated for online only publication, although, at the discretion of the editors, some may appear in the print journal as well. Articles in other categories, especially those that may appeal to only a narrow segment of the readership, may be accepted for online-only publication. Please note that online publication is considered a bonafide form of publication and can be cited using the DOI number located in the footnotes on the first page of each article.

    The full content of each regular monthly issue is routinely posted online at http://jaad.org.



    You can track your submitted article at http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

Advertisement

advert image